Ferring to invest CHF 30M in new biotech centre at Saint-Prex, Switzerland

Ferring Pharmaceuticals will invest approximately 30 million CHF over three years to build a new Ferring Biotech Centre at its existing headquarters and manufacturing site in Saint-Prex, Switzerland. The centre will include discovery, development and manufacturing capabilities for biologics and monoclonal antibodies.

“Ferring is committed to investing in innovative technology platforms to create new solutions for patients in our core areas of reproductive medicine and women’s health, gastroenterology and urology.”ferring.com

• 1 source
• ferring.comFerring announces 30 million CHF investment in new biotech centre in Switzerland - Ferring GlobalMore by pulseFeb 14, 2018

Summarized from public sources; check the original articles before acting on it.